Cargando…
Sorafenib improves the postoperative effect of early stage renal cell carcinoma
Sorafenib was examined to determine whether it improves postoperative effects during early stage renal cell carcinoma (RCC). A total of 133 patients with early renal clear cell carcinoma (T1-2N0M0) with surgical indications were continuously selected. The patients were divided into 3 groups accordin...
Autores principales: | Liu, Taiyang, Li, Jie, Wen, Xiuhua, Hui, Zhang, Qi, Gui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228338/ https://www.ncbi.nlm.nih.gov/pubmed/28105151 http://dx.doi.org/10.3892/ol.2016.5243 |
Ejemplares similares
-
Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006) -
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017) -
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
por: Qu, Xu-Dong, et al.
Publicado: (2012) -
Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009) -
Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma
por: Hsiao, Pojen, et al.
Publicado: (2019)